Sanmai Technologies PBC

Based in the US, Sanmai Technologies PBC offers innovative neuromodulation solutions through advanced ultrasound technology, focusing on enhancing brain health and wellness in patients with neurological conditions. Sanmai Technologies PBC, founded in 2020 in Sunnyvale, US, specializes in neuromodulation solutions. The company has raised a total of USD 12. 00 mn through its Series A funding round on July 4, 2025.

The firm has completed one deal to date, indicating its strategic focus on research and clinical partnerships in the neurotherapeutics sector. Sanmai Technologies develops neuromodulation solutions utilizing low-intensity transcranial ultrasound technology. Their flagship product is an investigational clinical ultrasound device aimed at various neurological conditions, offering non-invasive treatment options. The company is conducting trials to validate its technology, with plans to launch in select research clinics across North America and Europe, targeting research institutions and healthcare providers.

Sanmai Technologies operates a B2B model, generating revenue through partnerships with research clinics and healthcare institutions via collaborative agreements for clinical trials. These partnerships are structured to support long-term research initiatives, with future pricing determined based on trial outcomes and market conditions as the company prepares for market entry. Sanmai Technologies plans to leverage the recent Series A funding of USD 12. 00 mn to support the development and launch of new products, particularly its investigational clinical ultrasound device.

The firm aims to expand into additional markets in North America and Europe by 2026, enhancing its reach in the neurotherapeutics sector through strategic partnerships and collaborations.